MYCT1 (MYC Target 1), also known as MTLC or C1orf151. is a protein-coding gene implicated in cellular differentiation, proliferation, and apoptosis. It was initially identified as a transcriptional target of the MYC oncoprotein, a key regulator of cell growth and metabolism. MYCT1 is thought to play dual roles in both normal physiology and disease. In normal tissues, it contributes to developmental processes, particularly in the nervous and hematopoietic systems. However, dysregulation of MYCT1 has been linked to tumorigenesis, with studies showing aberrant expression in various cancers, including leukemia, neuroblastoma, and solid tumors.
Antibodies targeting MYCT1 are essential tools for studying its expression patterns, subcellular localization, and functional mechanisms. They enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Research using MYCT1 antibodies has revealed its nuclear and cytoplasmic distribution, suggesting potential roles in transcriptional regulation and signal transduction. Recent investigations highlight MYCT1's involvement in cancer progression, particularly through interactions with MYC-driven pathways, making it a candidate biomarker or therapeutic target. However, its precise molecular functions remain under exploration, necessitating further validation of antibody specificity and functional studies to clarify its pathophysiological significance.